EDSA Edesa Biotech, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1540159 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-138.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-122.9%
ROA-102.5%
ROIC (approx.)-9,500.4%
Asset turnover—
Leverage & solvency
Liabilities / assets30.7%
Debt / equity0.00x
Current ratio2.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-37.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $3.67M | $2.88M |
| SG&A expense | $4.24M | $4.13M |
| Operating income | -$7.91M | -$7.01M |
| Pretax income | -$7.18M | -$6.17M |
| Income tax | $800 | $800 |
| Net income | -$7.19M | -$6.17M |
| EBITDA | -$7.79M | -$6.83M |
| EPS (basic) | -1.27 | -1.93 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $10.79M | $1.04M |
| Current assets | $11.51M | $1.68M |
| PP&E, net | — | $0 |
| Intangibles | $1.98M | $2.08M |
| Total assets | $13.53M | $3.81M |
| Current liabilities | $1.08M | $1.83M |
| Total liabilities | $1.08M | $1.83M |
| Shareholders' equity | $12.45M | $1.98M |
| Shares outstanding | 7.14M | 3.25M |
| Cash flow statement | ||
| Operating cash flow | -$7.32M | -$4.89M |
| Financing cash flow | $17.03M | $592,031 |
| Depreciation & amortization | $119,273 | $186,049 |
| Stock-based compensation | $729,642 | $537,492 |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.